Chemical Structure (Levetiracetam 01)
Levetiracetam Solution
Product Images NDC 0121-2397
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 0121-2397). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Pai Holdings, Llc Dba Pai Pharma, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Levetiracetam 02)
This is a chart displaying percentages of patients for various treatment options. The treatment options include a placebo, Levetiracetam at 1000mg/day, and Levetiracetam at 3000mg/day. The chart provides percentages for each treatment option ranging from 0% to 45%. There are also percentages provided in increments of 5% from 5% to 45%.*
Figure 2 (Levetiracetam 03)
This is a table showing percentages of patients categorized by certain criteria. There are two groups - placebo and levetiracetam 1000 mg/day lev. However, the text alone is not sufficient to determine what the percentages represent or what the criteria are.*
Figure 3 (Levetiracetam 04)
This is a medical report showing the percentage of patients that participated in a clinical trial of levetiracetam at a dose of 3000 mg/day compared to a group that received a placebo treatment. The data shows that 14.4% of patients were in the placebo group (N=104) and 39.4% of patients were in the levetiracetam group (N=180).*
Figure 4 (Levetiracetam 05)
Figure 5 (Levetiracetam 06)
The text provided seems to describe statistics related to two groups of patients: one receiving a treatment called Levetracetum, with a sample size of 55, and one receiving a placebo, with a sample size of less than 51. The percentages mentioned (43.1% and 19.6%) may represent the proportion of patients in each group who experienced certain outcomes or side effects. However, there is not enough information to determine what those outcomes or side effects were.*
Figure 6 (Levetiracetam 07)
This appears to be a chart showing the percentage of patients in a study who may have responded positively to a placebo and to a drug called Levetiracetam. The percentages range from 0% to 100% in increments of 10%, and there are values of 45.2% and 72.2% listed for the placebo and Levetiracetam groups, respectively. However, the chart lacks any specific labels or context beyond the drug names, so it's not possible to determine the details of the study or what the response rates ultimately mean.*
Principal Display Panel (473 mL Bottle Label)
This is a product description for an oral solution of vetl'acetam, which has a recommended dosage and storage temperature. The solution comes in a 16 fluid ounce container and is kept in a tight, light-resistant container with a child-resistant closure to prevent the medication from getting into the hands of children. The accompanying medication guide is to be provided to each patient. The text includes a National Drug Code (NDC) number and mentions a USP Controlled Room for quality control.*
Principal Display Panel (5 mL Cup Label)
Delvers 5 mL ™ is an oral solution with a concentration of 500 mg/5 mL. The NDC number is 0121-4765-05 and the product comes in a package that is not child-resistant.*
Principal Display Panel (10 mL Cup Label)
This is an oral solution medication called Levetiracetam Y, manufactured by Pharmaceutical Associates, Inc in Greenville, SC. The NDC number is 0121-1598-10 and each bottle contains 10 mL of solution. The medication is available only with a prescription and the packaging is not child-resistant. Patients are advised to refer to the enclosed insert for directions and precautions.*
Principal Display Panel (15 mL Cup Label)
This is a pharmaceutical product identified as Levetiracetam Oral Solution, USP. It comes in a 15 mL bottle and has an NDC number of 0121-2307-15. It is manufactured by Pharmaceutical Associates Inc. located in Greenville, SC. The package is not child-resistant and it is only available through a prescription (Rx only). The product insert contains further information.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
